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tional study was performed. Pts who met inclusion criteria were followed-up for 12
months, with 3 visits programmed at baseline, 6 and 12 months. Baseline charac-
teristics and caregiver’s information were registered for every pt. Once identified
total hours, the replacement cost method was used. RESULTS: A total of 330 pt
were included, 74.2% men, mean age was 62.9 years. 82.4% were in NYHA class II,
16.4% NYHA class III and 1.2% NYHA class IV. A 28.5% needed support for daily
living. Ninety four informal caregivers were identified, mean age of 58yo, mostly
women (85.1%). Main relationship with caregiver was spouse/couple (77.7%), fol-
lowed by son/daughter (14.9%). Number of weekly hours of main caregiver was
estimated at 44.3 hours (40.6 hours for patients NYHA class II and 53.3 hours for
patients NYHA class III-IV) and shadow prices values from 8-13€/hour. Total costs
associated to informal caregiving increased between €21,298-€34,609 per pt of
which between €18,892-€30,049 are informal costs associated with the main care-
givers. Likewise, focusing on main caregivers, using the proxy-good method and
the shadow prices shown, the cost of replacing services by care giving a Class II
patient (2,115 yearly hours) were between €16,919-€27,494 for pts in NYHA class II;
and between €22,230-€36,123 for caregiving a Class III or IV pt (2,779 yearly hours).
CONCLUSIONS: Almost a 30% of pts with chronic symptomatic HF in Spain re-
quired support from an informal caregiver, which represents a significant burden
for society and often has not been accounted for in economic evaluations of treat-
ments for heart failure. Costs for informal care are associated with disease severity
as measured by NYHA class.
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OBJECTIVES: To evaluate the first-year direct medical cost for diagnosis and man-
agement of newly diagnosed SA, to identify SA-related resource consumption pat-
tern in public hospitals in the New Territories East Cluster in Hong Kong and in
patients with and without procedures, and with comorbidities of hypertension
(HTN), diabetes mellitus (DM) and hyperlipidemia.METHODS:A retrospective non-
randomized study was conducted including patients documented with new diag-
nosis of SA in the Clinical Management System during January 2007 to December
2009. Subjects were followed for 1 year after diagnosis. Cost items studied con-
sisted of hospitalization, clinic visits, diagnostic tests, radiological examinations,
laboratory tests, therapeutic operations and medications. For statistical analyses,
Mann-Whitney Tests were performed to compare medians of costs in patients with
and without procedures, and with different comorbidities of HTN, DM and hyper-
lipidemia. P-value 0.05 was regarded significant. RESULTS: 89 patients were re-
cruited. The mean first-year total direct medical cost of SA per patient was
HKD$89,518, with the cost for hospitalization being the most dominant, accounting
for 29.2%. Increase in complexity of disease would increase the total from
HKD$47,744 for patients without procedures to HKD$115,342 for patients with pro-
cedures (p0.001). For the three comorbidities interested, SA patients co-morbid
with hyperlipidemia required more resources for the management, HK$98,295
(p0.001).CONCLUSIONS:This study revealed the huge expenses incurred by SA in
the first year of initial diagnosis on local public healthcare system, which has a
significant implication on future resources allocation. Strategies for cost saving
and preventive measures should be implemented.
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OBJECTIVES:Dysphagia commonly occurs following stroke and contributes to sub-
sequent morbidity and mortality in stroke survivors with related substantial eco-
nomical implications. Literature on the burden of this medical condition is scarce.
This study aimed to identify the reported burden of dysphagia among stroke
patients. METHODS: Epidemiological data were collected from publications in
stroke and/or dysphagic patients and included prevalence of dysphagia and pneu-
monia, as its main complication. Economical data mainly included hospital length
of stay, and pneumonia treatment costs. RESULTS: The data demonstrate stroke
mostly occurs in people older than 65 years age (75%). Prevalence and epidemio-
logical figures varied widely from one publication to another. Indeed, up to 81% of
stroke patients were diagnosed as dysphagic, depending on the method and time
after stroke episode in which dysphagia is identified. Thus reportedly, up to 19.6
million stroke patients suffer dysphagia in North America and Europe. Studies
identified that 40% to 50% of dysphagic stroke patients aspirate. In addition, pneu-
monia occurs in up to 51% of dysphagic stroke patients. Of course, dysphagic stroke
patients who aspirate are at higher risk of pneumonia: up to 11-fold more than non
aspirators. In Europe and North America, up to more than 10 million dysphagic
stroke patients develop pneumonia. Furthermore hospital length of stay ranges
from 5.07 to 10.55 days for stroke patients with dysphagia versus 3.26 to 4.74 days
without dysphagia. The average hospital cost for pneumonia is $919 per day, total-
ing up to $96.5 billion in Europe and North America. CONCLUSIONS: The overall
dysphagia burden is substantial worldwide, especially in Europe and North Amer-
ica. It is probably underestimated since only direct medical costs were included.
However, it will most probably increase given the growing elderly population,
which is at higher risk of having stroke.
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OBJECTIVES: The aim of the present study is to estimate the annual direct and
indirect costs in patients with a history of or at risk for atherothrombosis in Greece,
using a bottom-up approach. METHODS: A multicentre, prospective, cost-of-ill-
ness study was conducted between January 2007 and December 2009. In this study,
800 patients with coronary artery disease (CAD) or cerebrovascular disease (CD) or
peripheral artery disease (PAD) or multiple cardiovascular risk factors (MRF) were
recruited from 11 major hospitals in Greece. All patients were followed up for 12
months. Resources used for the care of patients within the healthcare system and
productivity losses during the follow-up period were recorded. The annual direct
and indirect costs were calculated by combining these data with unit costs.
RESULTS: The mean annual total cost was €5,940/patient (€5,416–€6,522). This cost
ranges from €9,963/patient (€8,515–€11,868) for PAD group to €1,761/patient (€1,462–
€2,232) for MRF group. The mean annual direct healthcare cost was €5,056 /patient
(€4,653–€5,507). This cost escalates from €1,623 /patient (€1,319– €2,073) for MRF
group to € 8,697 /patient (€7,648– €9,695) for PAD group. The annual direct health-
care costs was mainly driven by vascular intervention costs among CAD and PAD
patients, (50.6% and 46.5%, respectively) and by the simple hospitalization cost
among CD and MRF patients (67.7% and 35.7%, respectively). The mean annual
indirect cost was €979 (€386– €1,395), €441 (€142- €835), €525 (€148 – €1,137) and €29
(€1- €87) per patient in the CD, CAD, PAD and MRF groups, respectively. The total
annual expenditures related to atherothrombosis, in Greece, are estimated to be 7.5
billion € at a national level. CONCLUSIONS: The findings of the THESIS study indi-
cate, for the first time, the high economic burden of atherothrombosis in Greece,
since the direct healthcare cost related to atherothrombosis management ac-
counts for almost 25% of annual healthcare expenditures.
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OBJECTIVES: Atrial fibrillation (AF) is the most common arrhythmia in clinical
practice and associated with a high risk of stroke. In Austria, about 130,000 people
are affected by AF. The first aim was to create a patient flow with epidemiological
data to close the research gap for Austria and further to estimate the total cost of
patients (direct and indirect costs) with AF and recommended oral anticoagulation.
METHODS: The model is based on these detected AF patients. The approach used
is prevalence-based, which is usually forgone within the time horizon of one year.
For 68% of these patients oral anticoagulation is recommended, but only 54% of
patients in the high-risk group received an OAC therapy. The remaining patients
get Aspirin (31%), other medication (5%) or no therapy (10%). Clinical-data and costs
of the adverse events stroke and major bleeding were considered. Direct costs
comprise all direct medical costs like consultation, lab test, inpatient costs, medi-
cation and treatment costs. Indirect costs represents costs for AF patients after
stroke like care allowance and costs of nursing homes. The resource use was de-
termined by literature and experts. All costs represent data from 2011. The burden
of disease study is conducted from a societal perspective. RESULTS: The direct
costs of AF patients amount to 51,972,668€ and the total costs inclusive indirect
costs are 93,915,299€ for the time horizon of one year. CONCLUSIONS: With rising
life expectancy the number of patients with AF and the prevalence of strokes will
increase. Therefore the time has come to give greater attention to the epidemio-
logical and socioeconomic burden of AF.
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OBJECTIVES: Interactions of mental illnesses and heart failure have been indi-
cated. Mental illness has been shown to be a risk factor of heart failure. In addition,
it may worsen the symptoms as well as compliance to the therapy of patients with
heart failure. A recent study has showed that comorbid depression may be associ-
ated with higher medical costs. The purpose of this study was to assess the impact
of comorbid mental illness on costs of health care for inpatients with heart failure.
METHODS: A retrospective cohort study of inpatients with heart failure. Data were
collected between July 1, 2008, and December 31, 2008 from 855 acute care hospitals
in Japan. In total, 38,446 admissions of patients with heart failure in 855 hospitals
were included in the analysis. We compared health care costs of 5 groups: 1) no
mental illness; 2) antidepressant prescription only; 3) co-prescription of antide-
pressant and other psychotropic drugs; 4) antidepressant prescription and depres-
sion diagnosis recorded; and 5) anxiolytic or hypnotic prescription only. Statistical
analyses were performed using JMP 8.0. RESULTS: Psychotropic drugs were used in
19,839 (51.6%) patients with heart failure. The average number of psychotropic
drugs was 3.69 per hospitalization in heart failure inpatients. After adjustment for
covariates, patients prescribed with psychotropic drugs had significantly higher
costs than patients not prescribed. CONCLUSIONS: This study suggested that co-
morbid mental illness is associated with higher medical costs.
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